Kathryn Atkins, Author at Oncotarget

Oncotarget News

Oncotarget

Oncotarget | HALP Score: Prognostic Ability in Cancers – A Literature Review

March 6, 2023

In the last several years, the Hemoglobin, Albumin, Lymphocyte, Platelet Score (HALP) has emerged in the literature as a new prognostic biomarker [...]” BUFFALO, NY- March 6, 2023 – A new... read more

Oncotarget

Oncotarget | Unveiling the Non-canonical Functions of EZH2 in Prostate Cancer

March 3, 2023

In summary, both articles by Yi et al. emphasized the significance of non-canonical functions of EZH2 during PCa [prostate cancer] development [...]” BUFFALO, NY- March 3, 2023 – A new editorial... read more

Figure 1: Comparison of progression-free survival (A) and overall survival (B) between children (

Oncotarget

Oncotarget | WNT-pathway Medulloblastoma: What Constitutes Low-risk and How Low Can One Go?

February 27, 2023

The definition of low-risk WNT-pathway medulloblastoma may need to be refined in light of recent clinical data and newer biological information.” BUFFALO, NY- February 27, 2023 – A new research... read more

Oncotarget

Oncotarget | Oncogenic Driver FGFR3-TACC3 Requires 5 Coiled-coil Heptads for Activation and Disulfide Bonds for Stability

February 23, 2023

Together, this work highlights the need to investigate different breakpoints of fusion proteins, as they may potentially lack the necessary biological activity required for oncogenesis, ultimately leading to misidentification of... read more

Oncotarget

Oncotarget | Extreme Phenotype Approach Identifies Rare ATR Variants as Potential Male Breast Cancer Susceptibility Alleles

February 21, 2023

Basic functions of ATR classify it in the category of tumor suppressor genes but further studies show that its role is more complex in the context of cancer.” BUFFALO,... read more

Figure 3: Cancer-specific survival curve based on the inflammation-based prognostic index. Abbreviation: ICPI: inflammation based prognostic index.

Oncotarget

Oncotarget | Novel Prognostic Index to Predict Survival Outcomes in Gastric Cancer Patients

February 14, 2023

In this study, the ICPI [inflammation-combined prognostic index] was devised as a novel predictive index of prognosis, and its usefulness was clarified.” BUFFALO, NY- February 14, 2023 – A new... read more

Figure 4: Everolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts.

Oncotarget

Oncotarget | Everolimus Inhibits Angiogenesis and Lymphangiogenesis in TP53 Mutant HNSCC by Downregulating STAT3/HIF-1α/VEGF Pathway

February 9, 2023

we sought to investigate the mechanism for everolimus-induced inhibition of TP53 HNSCC.” BUFFALO, NY- February 9, 2023 – A new research paper was published in Oncotarget's Volume 14 on February... read more

Figure 1: Multiple mechanisms underly the pro-tumorigenic role of CD200.

Oncotarget

Oncotarget | Immunoregulatory Protein CD200 as Potentially Lucrative Yet Elusive Target for Cancer Therapy

February 7, 2023

CD200 expression is reported across most cancer types [...]” BUFFALO, NY- February 7, 2023 – A new research perspective was published in Oncotarget's Volume 14 on February 4, 2023, entitled, “The... read more

Figure 2: Kaplan–Meier curve for estimated median DOR in the DLBCL combined cohort (response-evaluable population).

Oncotarget

Oncotarget | Mivavotinib for Relapsed/Refractory B-cell Lymphoma (Updated)

February 1, 2023

The current analysis provides updated results for these lymphoma patients with extended follow-up.” BUFFALO, NY- February 1, 2023 – A new research paper was published in Oncotarget's Volume 14 on... read more

Figure 1: Putative mechanisms of toxicity. immunovirotherapy

Oncotarget

Oncotarget | Intraventricular Immunovirotherapy; A Translational Step Forward

January 26, 2023

Immunotherapies, including oncolytic virotherapy, offer novel, targeted approaches to treat brain tumors with increased efficacy and reduced toxicity [5].” BUFFALO, NY- January 26, 2023 – A new research perspective was... read more